comparemela.com

Latest Breaking News On - E3 2022 - Page 1 : comparemela.com

Armata Pharmaceuticals Inc (ARMP) Reports Q3 2023 Financial Results and Corporate Updates

Continued Progress in Phage Therapeutics Development Amidst Increased Expenses

Deborah birxArmata pharmaceuticalsDepartment of defenseAnalysis of company performanceArmata pharmaceuticals incTailwind phaseBalance sheetCash flowsAdministrative expensesAsh and cash equivalentsResearch and developmentE3 2022E3 2023

UroGen Pharma Ltd (URGN) Reports Growth in Q3 Revenue and Progress in Clinical Trials

Net Revenue Rises as Company Advances with UGN-102 Clinical Development

Liz barrettClinical developmentUrogen pharma ltdIncome statementProduct revenueProduct revenuesE3 2022Research and development expensesNet loss

Sanara MedTech Inc Reports Record Sales in Q3 2023 with Narrowed Net Loss and Positive

Strategic Acquisitions and Product Launches Propel Growth Amidst Operational Challenges

District of columbiaUnited statesSanara medtech incSanara medtechNew productSanara medtech incMarket challengesSanara medtech incNet lossE3 2022E3 2023

electroCore Inc (ECOR) Reports Substantial Sales Growth in Q3 2023

Net Sales Surge by 128% Year-Over-Year; Company Raises Full-Year Revenue Guidance

Core incDepartment of defenseDepartment of veteran affairsVeteran affairsInvestor relationsRevenue guidanceFinancial resultsNet lossE3 2022

Fulcrum Therapeutics Inc (FULC) Reports Q3 2023 Financial Results and Business Highlights

Company's cash runway extended into 2026, with a net loss of $24.0 million for Q3 2023

Alexc sapirFulcrum therapeutics incIopharmaceutical companySickle cell diseaseCash equivalentsFacioscapulohumeral muscular dystrophyFulcrum therapeuticsE3 2022Clinical developmentCash positionMarketable securities

vimarsana © 2020. All Rights Reserved.